Precision Management of Advanced Non-Small Cell Lung Cancer

Annu Rev Med. 2020 Jan 27:71:117-136. doi: 10.1146/annurev-med-051718-013524.

Authors

Ching-Yao Yang¹, James Chih-Hsin Yang², Pan-Chyr Yang^{1

3}

Affiliations

¹ Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; email: pcyang@ntu.edu.tw.
² Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
³ Institute of Biomedical Sciences and Genomics Research Center, Academia Sinica, Taipei, Taiwan.

PMID: 31986082
DOI: 10.1146/annurev-med-051718-013524

Abstract

The rapid evolution of treatment for advanced lung cancer is a story of how scientists have struggled to move from nonselective cytotoxic chemotherapy to personalized precision medicine. In this century, extraordinary advances have been made in the management of advanced and metastatic non-small cell lung cancer, especially in the development of small molecules targeting specific tyrosine kinase receptors and immune checkpoint inhibitors. These developments have led to a significant improvement in survival for lung cancer patients with metastatic disease. Now, the core guidelines to treat non-small cell lung cancer are based on the identification of targetable driver mutations and immune checkpoints. Continued investigations of newly identified druggable genetic alterations, explorations of biomarkers of immune checkpoint inhibitors, development of next-generation immunotherapy, and optimization of combination therapy are necessary to provide better treatment outcomes for lung cancer patients in the future.

Keywords: immunotherapy; non–small cell lung cancer; precision medicine; targeted therapy.

Publication types

Review

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Anaplastic Lymphoma Kinase / antagonists & inhibitors
Anaplastic Lymphoma Kinase / genetics
Angiogenesis Inhibitors / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / genetics
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Molecular Targeted Therapy
Precision Medicine
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / genetics

Substances

Angiogenesis Inhibitors
Antineoplastic Agents, Immunological
B7-H1 Antigen
Programmed Cell Death 1 Receptor
Protein Kinase Inhibitors
Anaplastic Lymphoma Kinase
ErbB Receptors
Proto-Oncogene Proteins B-raf